Citizens JMP Reiterates Market Outperform Rating on Prelude Therapeutics (PRLD)
Tweet Send to a Friend
Citizens JMP analyst Reni Benjamin reiterated a Market Outperform rating and $4.00 price target on Prelude Therapeutics (NASDAQ: PRLD).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


